Figure 6.

DOAC‐Stop allows the identification of clot‐based‐only positives and triple‐positive patients with APS receiving rivaroxaban. (A) A flow diagram is depicted starting on the left with each of the samples from our test cohort separated by medication (n = 73 samples). The second, or middle, node group indicates whether the patients providing these samples tested positive for a LAC (clot‐based positive) or were positive by ELISA only, or had completely negative/unknown results for both clot‐based and ELISA detectable antiphospholipid antibodies. The third, or right‐most, node group indicates the ELISA results for patients who tested positive for a LAC by clot‐based testing (n = 6). Two were positive only by clot‐based testing (functional assay only Positive, red star), and four were triple positive for LAC, ACA, and aβ2GPI antibodies. Of note, there were no double‐positive cases. (B) The subset of the data presented in (A) highlighting the samples from patients on rivaroxaban. The presence of two triple‐positive cases is indicated by a red star. The number immediately adjacent to each node indicates the quantity of specimens. ACA, anticardiolipin; aβ2GPI, anti‐β2‐glycoprotein I; APS, antiphospholipid syndrome; LAC, lupus anticoagulant antibody